Safety and Immunogenicity of HIL-214 With Routine Pediatric Vaccines

Summary

This is a phase 2, multi-country, randomized, double-blind, placebo-controlled trial to evaluate the immune response to routine pediatric vaccinations when co-administered with HIL-214 or placebo in healthy infants. This trial will also evaluate the safety profile of a 2-dose regimen of HIL-214 co-administered with routine pediatric vaccines.

Timeline

Start

2023-06-10

Primary completion

2024-01-19

Completion

2024-07-08

Drugs

Indications